ClinicalTrials.gg
CompletedNCT01424397Updated Sep 13, 2019Results posted

Intranasal SB-705498 in Allergic Rhinitis (AR) Patients

A Phase 2 interventional study of SB-705498 and FP in Rhinitis, sponsored by GlaxoSmithKline. Completed at 1 site in Austria. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-13.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2011, registered Aug 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 25 studies in Rhinitis by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Rhinitis · GlaxoSmithKline.

Enrollment
8th of 21
70 · median 56
Started
2011
with 2 others
Phase 2
8 of 25
none open now
Registered
8th of 25
by date

Among the 25 studies in Rhinitis by GlaxoSmithKline, this one is the 8th largest by enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2011, is one of 8 in phase 2, and was the 8th registered.

Rhinitis

246 studies on the registry are indexed under Rhinitis; 22 are open to participants now.

Browse Rhinitis studies →

Open to participants now

None of the 25 studies in Rhinitis by GlaxoSmithKline is open now. The open studies under Rhinitis, anywhere →

Who these studies take

Of the 15 Rhinitis studies recruiting now, 4 (27%) set no upper age limit and 10 (67%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 25 studies in Rhinitis by GlaxoSmithKline as a file.
02

Study summary

This study is designed to look at the affect of SB-705498 on allergic rhinitis symptoms induced by an allergen chamber challenge.

03

Conditions studied

  • Rhinitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of AR, as determined by the presence of rhinitis symptoms that last for several months per year, for more than 1 year and are not attributed to allergy, infections or nasal abnormalities.
  2. TNSS score of >=4 following screening allergen challenge chamber.
  3. Positive skin prick test for seasonal pollen
  4. Positive RAST for seasonal pollen
  5. Healthy as determined by responsible physician with the exception of mild asthma and AR
  6. Male or female between 18 and 65 years of age inclusive.
  7. A female subject is eligible to participate if she is of:

    • Non- defined as pre-menopausal females with a \documented tubal ligation or hysterectomy; or defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol \< 40 pg/ml (\<147 pmol/L) is confirmatory].
    • Child-bearing potential and agrees to use one of the methods listed as instructed. Female subjects must agree to use contraception until 84 days post-last treatment administration.
  8. Male subjects with female partners of child-bearing potential must agree to use one contraception as instructed. This must be followed from the time of the first dose of study medication until 84 days post-last treatment administration.
  9. Body weight ≥ 50 kg (males) and ≥45kg (females) and within the range 19 - 29.9 kg/m2 (inclusive).
  10. Screening pre-challenge greater than or equal to 80% and baselines FEV1/FVC greater than or equal to 70% of predicted value.
  11. Capable of giving written .
  12. Average , \< 450 msec; or QTc \< 480 msec in subjects with Bundle Branch Block.
  13. and ALT \< 2xULN; alkaline phosphatase and less than or equal to 1.5xULN

Exclusion criteria

Exclusion Criteria:

  1. Nasal abnormalities likely to affect the outcome of the study,
  2. History of frequent nosebleeds.
  3. Respiratory disease other than mild asthma
  4. A positive pre-study or result within 3 months of screening
  5. Current or chronic history of liver disease, or known hepatic or biliary abnormalities
  6. Positive pre-study drug/alcohol/smoking screen.
  7. A positive test for antibody.
  8. History of regular alcohol consumption within 6 months of the study defined as:

    • An average weekly intake of >14 drinks for males or >7 drinks for females.
  9. The subject has participated in a clinical trial and has received an product within 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product prior to D1.
  10. Exposure to more than four new chemical entities within 12 months prior to D1.
  11. Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days prior to the first dose of study medication.
  12. History of sensitivity to any of the study medications, or components
  13. Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  14. Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  15. Lactating females.
  16. Subject is mentally or legally incapacitated.
  17. Urine cotinine levels indicative of smoking
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    SB-705498

    Experimental

    Drug: SB-705498

  • Active comparator
    Fluticasone Propionate

    Active Comparator

    Drug: FP

  • Placebo comparator
    Placebo

    Placebo Comparator

    Drug: placebo

  • Experimental
    SB-705498+FP

    Experimental

    Drug: SB-705498 · Drug: FP

Interventions

  • 12mg intranasal

  • DrugFP

    200ug intranasal

  • Drugplacebo

    placebo intranasal

06

What researchers measure

Primary outcomes

  1. Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8

    Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Weighted mean (WM) of TNSS and its individual components (nasal congestion, rhinorrhoea, itching and sneezing) are presented on Day 8. Weighted mean was calculated over the time interval 0 to 4 hours after start of allergen chamber challenge by calculating the area under the curve of TNSS/component from time of the first observation to time of the last observation (AUC \[tf-t1 hours\]) using the trapezoidal rule, and then dividing by the actual relevant time interval (tf-t1) required by participant to complete the chamber challenge assessments. A Bayesian analysis was conducted to derive the posterior probability for TNSS.

    Time frame: Day 8 of each treatment period

Secondary outcomes

  1. Mean TNSS and Its Individual Components From Day 4 to Day 8

    Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Mean of TNSS and its individual components is presented pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge \[1 hour (hr)\] on Day 8.

    Time frame: pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge [1 hour (hr)] on Day 8 of each treatment period

  2. Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)

    Total Nasal Airflow is calculated as the sum of the left nostril and the right nostril airflow values. AAR is a very sensitive method of assessing clinical parameters of nasal obstruction (nasal flow, nasal resistance and nasal flow increase). A participant was instructed to breathe through one nostril while a sensor in the other nostril measured the difference in pre-nasal and choanal pressure. The system was connected to a computer. Nasal flow and nasal resistance were observed at pressure levels of 75, 150 and 300 Pascal. The defined measuring range for the flow was +-1000 milliliter per second (mL/s). Weighted means for total nasal airflow Resistance was calculated by dividing the area under the curve between 1 and 4 hours (via the linear trapezoidal method) by the total duration that the participant took to complete the chamber challenge assessments.

    Time frame: Day 8

  3. Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo

    The RQLQ composed of 28 items covering 7 domains of health. Each question is scored on a scale of 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). 7 domains were: Activities (3 items):1, 2, 3;Sleep (3 items): 4, 5, 6; Non-nose/eye symptoms (7 items): 7, 8, 9, 10, 11, 12, 13; Practical Problems (3 items): 14, 15, 16; Nasal Symptoms (4 items): 17, 18, 19, 20; Eye Symptoms (4 items): 21, 22, 23, 24; Emotional (4 items): 25, 26, 27, 28 consisted of total 28 items. Domain activity score = total post-baseline score for individualized activity items answered on both visits divided by total Baseline score for individualized activity items answered on both visits multiplied by the Baseline score for item(s) missing post-baseline. The global RQLQ score was calculated by averaging all 28 item scores, which ranges from 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). Higher scores indicate worsening of symptoms.

    Time frame: Day 8

  4. Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8

    Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.

    Time frame: Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)

  5. Maximum Observed Concentration (Cmax) for SB-705498 on Day 8

    Plasma samples for pharmacokinetic analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as least squares geometric means with respective geometric coefficient of variation (% CV).

    Time frame: Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)

  6. Number of Participants With Vital Signs of Potential Clinical Importance (PCI)

    Vital signs assessment included heart rate, blood pressure, and temperature. Criteria for vital sign values meeting potential clinical concern included: systolic blood pressure (SBP) \<85 and \>160 millimeters of mercury (mm Hg), diastolic blood pressure (DBP) \< 45 and \> 100 mm Hg, temperature \<36 and \>37.5 Degree Celsius and heart Rate \<40 and \>110 beats per minute. Only parameters with PCI values are reported.

    Time frame: Up to Week 16

  7. Change From Baseline in ECG Values: Heart Rate

    Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, and QTc intervals. Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

    Time frame: Baseline and Day 8 of each treatment period

  8. Change From Baseline in ECG Values: PR Interval, QRS Duration, QT Interval, QTcB, QTcF

    Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, QTc corrected by Bazett's formula (QTcB) and QTc corrected by Fridericia's formula (QTcF). Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

    Time frame: Baseline and Day 8 of each treatment period

  9. Number of Participants With Hematology Parameters of PCI

    The PCC range for hematology parameters included white blood cell count, low: 0.67, high 1.82, neutrophil count, low: 0.83, Hemoglobin, male- high 1.03, female- high 1.13, hematocrit, male- high 1.02, female- high 1.17, Platelet Count, low: 0.67, high: 1.57, lymphocytes, low 0.81. Only parameters with PCI values are reported.

    Time frame: Up to Week 16

  10. Number of Participants With Clinical Biochemistry Parameters of PCI

    The PCC range for clinical chemistry parameters included albumin, low: 0.86, millimole per liter (mmol)/L, calcium, low: 0.91, high: 1.06, glucose. Low: 0.71, high: 1.41, Potassium, low: 0.86, high: 1.10, Sodium, low: 0.96, high: 1.03, Total CO2, Low: 0.86, high: 1.14, Creatinine, in male, Low: \<75 micromole per liter (μmol/L), high: \>110 μmol/L, female, Low: \<65 μmol/L, high: \>95, Blood Urea Nitrogen (BUN), high: \>1.5xULN mmol/L, Uric Acid, in male, Low: \< 180 μmol/L, high: \> 480 μmol/L, female, Low: \< 120 μmol/L, high: \> 420. Only parameters with PCI values are reported.

    Time frame: Up to Week 16

07

Results

Posted Sep 13, 2019

Participant flow

A total of 70 male and female participants with a history of allergic rhinitis (AR) were enrolled in this study. Study period was 14 April 2011 to 07 July 2011.

Period-1 (8 Days)
Participant flow — Period-1 (8 Days)
MilestoneTreatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then A
Started788888444344
Completed788888444344
Not completed000000000000
Washout Period-1 (14-20 Days)
Participant flow — Washout Period-1 (14-20 Days)
MilestoneTreatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then A
Started788888444344
Completed788888444344
Not completed000000000000
Period-2 (8 Days)
Participant flow — Period-2 (8 Days)
MilestoneTreatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then A
Started788888444344
Completed787888444344
Not completed001000000000
Withdrew: Withdrawal by subject001000000000
Washout Period-2 (14-20 Days)
Participant flow — Washout Period-2 (14-20 Days)
MilestoneTreatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then A
Started787888444344
Completed787888444344
Not completed000000000000
Period-3 (8 Days)
Participant flow — Period-3 (8 Days)
MilestoneTreatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then A
Started787888444344
Completed787888444344
Not completed000000000000

Outcome measures

PrimaryMean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8

Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Weighted mean (WM) of TNSS and its individual components (nasal congestion, rhinorrhoea, itching and sneezing) are presented on Day 8. Weighted mean was calculated over the time interval 0 to 4 hours after start of allergen chamber challenge by calculating the area under the curve of TNSS/component from time of the first observation to time of the last observation (AUC \[tf-t1 hours\]) using the trapezoidal rule, and then dividing by the actual relevant time interval (tf-t1) required by participant to complete the chamber challenge assessments. A Bayesian analysis was conducted to derive the posterior probability for TNSS.

Time frame:
Day 8 of each treatment period
Reported as:
Mean · Score on scale
Mean Total Nasal Symptom Score (TNSS) and Its Individual Components on Day 8
Score on scalePlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
TNSS WM6.53 ± 2.3003.65 ± 2.3606.57 ± 2.4184.14 ± 2.243
Nasal congestion scoreWM1.80 ± 0.6531.15 ± 0.7921.82 ± 0.6481.18 ± 0.715
Rhinorrhoea score WM1.67 ± 0.6930.94 ± 0.7261.75 ± 0.6971.05 ± 0.687
Nasal itching score WM1.67 ± 0.7600.94 ± 0.7081.57 ± 0.8861.17 ± 0.699
Sneezing score WM1.39 ± 0.7630.62 ± 0.5731.43 ± 0.7850.74 ± 0.560
Statistical analysis
  • Placebo vs FP 200 μg ·
  • Placebo vs SB-705498 12 mg ·
  • Placebo vs SB-705498 + FP 12 mg ·
  • FP 200 μg vs SB-705498 + FP 12 mg ·
SecondaryMean TNSS and Its Individual Components From Day 4 to Day 8

Nasal symptoms (nasal congestion, rhinorrhoea, itching and sneezing) were scored on a scale from 0 to 3 where 0= absent symptoms, 3 = severe symptoms. TNSS was calculated as the sum of the response for all 4 individual nasal symptom scores. TNSS ranged from 0 to 12, where 0=absent symptoms, 3=severe symptoms. Higher the score, more severe the symptoms. Mean of TNSS and its individual components is presented pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge \[1 hour (hr)\] on Day 8.

Time frame:
pre-evening (pm) dose on Days 4, 5, 6, 7 and pre-challenge [1 hour (hr)] on Day 8 of each treatment period
Reported as:
Mean · Score on a scale
Mean TNSS and Its Individual Components From Day 4 to Day 8
Score on a scalePlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
TNSS,Day 4, pre-pm dose3.6 ± 2.472.4 ± 2.203.3 ± 2.652.6 ± 1.94
TNSS,Day 5, pre-pm dose3.6 ± 2.582.0 ± 2.242.9 ± 2.602.3 ± 2.10
TNSS,Day 6, pre-pm dose3.3 ± 2.451.8 ± 2.032.8 ± 2.742.0 ± 2.03
TNSS,Day 7, pre-pm dose3.2 ± 2.261.7 ± 1.902.2 ± 2.371.9 ± 2.12
TNSS,Day 8, pre-challenge (1hr)2.0 ± 1.881.3 ± 1.601.9 ± 1.521.1 ± 1.45
Nasal congestion score code,Day 4, pre-pm dose1.0 ± 0.810.8 ± 0.690.9 ± 0.950.7 ± 0.65
Nasal congestion score code,Day 5, pre-pm dose0.9 ± 0.820.7 ± 0.700.7 ± 0.880.6 ± 0.64
Nasal congestion score code,Day 6, pre-pm dose0.9 ± 0.800.7 ± 0.740.8 ± 0.830.6 ± 0.68
Nasal congestion score code,Day 7, pre-pm dose0.8 ± 0.690.6 ± 0.620.7 ± 0.820.6 ± 0.65
Nasal congestion score code,Day 8, pre-challenge0.7 ± 0.670.6 ± 0.670.6 ± 0.590.4 ± 0.58
Rhinorrhoea score code,Day 4, pre-pm dose0.9 ± 0.710.6 ± 0.760.9 ± 0.870.5 ± 0.65
Rhinorrhoea score code,Day 5, pre-pm dose0.9 ± 0.750.5 ± 0.780.9 ± 0.900.5 ± 0.66
Rhinorrhoea score code,Day 6, pre-pm dose0.8 ± 0.730.4 ± 0.650.8 ± 0.900.6 ± 0.62
Rhinorrhoea score code,Day 7, pre-pm dose0.8 ± 0.650.4 ± 0.620.6 ± 0.780.4 ± 0.69
Rhinorrhoea score code,Day 8, pre-challenge (1hr)0.6 ± 0.690.3 ± 0.590.6 ± 0.660.3 ± 0.50
Nasal itching score code,Day 4, pre-pm dose0.9 ± 0.850.5 ± 0.660.7 ± 0.710.7 ± 0.71
Nasal itching score code,Day 5, pre-pm dose0.8 ± 0.810.4 ± 0.630.4 ± 0.660.7 ± 0.75
Nasal itching score code,Day 6, pre-pm dose0.8 ± 0.840.3 ± 0.580.5 ± 0.730.5 ± 0.72
Nasal itching score code,Day 7, pre-pm dose0.8 ± 0.800.4 ± 0.620.3 ± 0.650.5 ± 0.72
Nasal itching score code,Day 8, pre-challenge (1hr0.5 ± 0.650.3 ± 0.600.3 ± 0.490.3 ± 0.55
Sneezing score code,Day 4, pre-pm dose0.9 ± 0.780.5 ± 0.680.9 ± 0.870.6 ± 0.68
Sneezing score code,Day 5, pre-pm dose0.9 ± 0.850.4 ± 0.670.8 ± 0.830.4 ± 0.65
Sneezing score code,Day 6, pre-pm dose0.8 ± 0.820.4 ± 0.570.7 ± 0.920.4 ± 0.68
Sneezing score code,Day 7, pre-pm dose0.8 ± 0.750.3 ± 0.550.5 ± 0.730.4 ± 0.61
Sneezing score code,Day 8, pre-challenge (1hr)0.3 ± 0.510.1 ± 0.260.4 ± 0.580.1 ± 0.31
SecondaryTotal Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)

Total Nasal Airflow is calculated as the sum of the left nostril and the right nostril airflow values. AAR is a very sensitive method of assessing clinical parameters of nasal obstruction (nasal flow, nasal resistance and nasal flow increase). A participant was instructed to breathe through one nostril while a sensor in the other nostril measured the difference in pre-nasal and choanal pressure. The system was connected to a computer. Nasal flow and nasal resistance were observed at pressure levels of 75, 150 and 300 Pascal. The defined measuring range for the flow was +-1000 milliliter per second (mL/s). Weighted means for total nasal airflow Resistance was calculated by dividing the area under the curve between 1 and 4 hours (via the linear trapezoidal method) by the total duration that the participant took to complete the chamber challenge assessments.

Time frame:
Day 8
Reported as:
Least squares mean · Milliliters per second (mL/s)
Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)
Milliliters per second (mL/s)PlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Total Nasal Airflow on Day 8 Measured Using Active Anterior Rhinomanometry (AAR)306.99 ± 17.255388.34 ± 17.207299.68 ± 22.806379.40 ± 18.783
Statistical analysis
  • Placebo vs FP 200 μg · Mean difference (net): 81.35 · 90% CI 60.54 to 102.15
  • Placebo vs SB-705498 12 mg · Mean difference (net): -7.31 · 90% CI -39.7 to 25.05
  • Placebo vs SB-705498 + FP 12 mg · Mean difference (net): 72.40 · 90% CI 48.28 to 96.52
  • FP 200 μg vs SB-705498 + FP 12 mg · Mean difference (net): -8.95 · 90% CI -33.1 to 15.22
SecondaryRhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo

The RQLQ composed of 28 items covering 7 domains of health. Each question is scored on a scale of 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). 7 domains were: Activities (3 items):1, 2, 3;Sleep (3 items): 4, 5, 6; Non-nose/eye symptoms (7 items): 7, 8, 9, 10, 11, 12, 13; Practical Problems (3 items): 14, 15, 16; Nasal Symptoms (4 items): 17, 18, 19, 20; Eye Symptoms (4 items): 21, 22, 23, 24; Emotional (4 items): 25, 26, 27, 28 consisted of total 28 items. Domain activity score = total post-baseline score for individualized activity items answered on both visits divided by total Baseline score for individualized activity items answered on both visits multiplied by the Baseline score for item(s) missing post-baseline. The global RQLQ score was calculated by averaging all 28 item scores, which ranges from 0 to 6 (where, 0 = not troubled and 6 = extremely troubled). Higher scores indicate worsening of symptoms.

Time frame:
Day 8
Reported as:
Least squares mean · Score on a scale
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo
Score on a scalePlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) Following Repeat Doses of SB-705498 or or SB-705498 Matching Placebo1.67 ± 0.1190.99 ± 0.1181.66 ± 0.1771.14 ± 0.135
Statistical analysis
  • Placebo vs FP 200 μg · Mean difference (net): -0.68 · 90% CI -0.87 to -0.49
  • Placebo vs SB-705498 12 mg · Mean difference (net): -0.01 · 90% CI -0.30 to 0.27
  • Placebo vs SB-705498 + FP 12 mg · Mean difference (net): -0.52 · 90% CI -0.74 to -0.31
  • FP 200 μg vs SB-705498 + FP 12 mg · Mean difference (net): 0.15 · 90% CI -0.06 to 0.37
SecondaryArea Under Concentration-time Curve (AUC) for SB-705498 on Day 8

Plasma samples for pharmacokinetic (PK) analysis were drawn at indicated time points of each treatment period. AUC0-t was calculated by the linear trapezoidal method. AUC0-infinity was calculated as the sum of the AUC0-t plus the ratio of the last measurable plasma concentration to the elimination rate constant, where first-order elimination or terminal rate constant was calculated from a semi-log plot of the plasma concentration versus time curve. The parameter was calculated by linear least-squares regression analysis using the last three (or more) non-zero plasma concentrations. Values were reported as Least Squares Geometric Means with respective % CV.

Time frame:
Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)
Reported as:
Geometric mean · nanograms*hour per mililiter (ng.h/mL)
Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8
nanograms*hour per mililiter (ng.h/mL)SB-705498 12 mgSB-705498 + FP 12 mg
Area Under Concentration-time Curve (AUC) for SB-705498 on Day 8588.26 ± 71.4608.84 ± 74.2
SecondaryMaximum Observed Concentration (Cmax) for SB-705498 on Day 8

Plasma samples for pharmacokinetic analysis were drawn at indicated time points of each treatment period. Cmax was defined as maximal measured plasma concentration over the time span specified. Values were reported as least squares geometric means with respective geometric coefficient of variation (% CV).

Time frame:
Period 1: Day 1 (post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h), Period 2 and 3: Day 1 (Pre-dose 0.0 h, post dose 1 and 5 h) and 8 (Pre-dose (0.0 h), post dose 1 and 5 h)
Reported as:
Geometric mean · nanograms per mililiter (ng/mL)
Maximum Observed Concentration (Cmax) for SB-705498 on Day 8
nanograms per mililiter (ng/mL)SB-705498 12 mgSB-705498 + FP 12 mg
Maximum Observed Concentration (Cmax) for SB-705498 on Day 8145.958 ± 68.8154.231 ± 71.0
SecondaryNumber of Participants With Vital Signs of Potential Clinical Importance (PCI)

Vital signs assessment included heart rate, blood pressure, and temperature. Criteria for vital sign values meeting potential clinical concern included: systolic blood pressure (SBP) \<85 and \>160 millimeters of mercury (mm Hg), diastolic blood pressure (DBP) \< 45 and \> 100 mm Hg, temperature \<36 and \>37.5 Degree Celsius and heart Rate \<40 and \>110 beats per minute. Only parameters with PCI values are reported.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Vital Signs of Potential Clinical Importance (PCI)
ParticipantsPlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Temperature,Low,period 32000
Temperature,Low,Follow up2100
SecondaryChange From Baseline in ECG Values: Heart Rate

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, and QTc intervals. Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

Time frame:
Baseline and Day 8 of each treatment period
Reported as:
Mean · beats per minute (bpm)
Change From Baseline in ECG Values: Heart Rate
beats per minute (bpm)PlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Change From Baseline in ECG Values: Heart Rate-0.2 ± 11.32-4.7 ± 10.80-4.8 ± 8.09-2.6 ± 11.19
SecondaryChange From Baseline in ECG Values: PR Interval, QRS Duration, QT Interval, QTcB, QTcF

Single 12-lead ECGs were obtained at each time point during the study using an ECG machine that automatically calculated heart rate and measured PQ, QRS, QT, QTc corrected by Bazett's formula (QTcB) and QTc corrected by Fridericia's formula (QTcF). Baseline was assessment on Day 1. Change from Baseline was the values at specified time points subtracted by the Baseline value.

Time frame:
Baseline and Day 8 of each treatment period
Reported as:
Mean · Milliseconds (msec)
Change From Baseline in ECG Values: PR Interval, QRS Duration, QT Interval, QTcB, QTcF
Milliseconds (msec)PlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
PR Interval2.7 ± 8.31-1.2 ± 9.384.5 ± 9.290.4 ± 9.73
QRS Duration0.8 ± 6.302.2 ± 5.520.8 ± 5.92-0.2 ± 5.05
QT Interval-1.5 ± 21.474.6 ± 22.12-0.3 ± 17.502.5 ± 17.93
QTcB-3.6 ± 17.30-9.3 ± 18.44-13.9 ± 20.79-4.1 ± 21.10
QTcF-2.9 ± 13.16-4.4 ± 13.37-9.0 ± 16.53-1.9 ± 13.33
SecondaryNumber of Participants With Hematology Parameters of PCI

The PCC range for hematology parameters included white blood cell count, low: 0.67, high 1.82, neutrophil count, low: 0.83, Hemoglobin, male- high 1.03, female- high 1.13, hematocrit, male- high 1.02, female- high 1.17, Platelet Count, low: 0.67, high: 1.57, lymphocytes, low 0.81. Only parameters with PCI values are reported.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Hematology Parameters of PCI
ParticipantsPlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Total Neutrophils,low7924
Hematocrit,high0010
Hemoglobin,high0010
SecondaryNumber of Participants With Clinical Biochemistry Parameters of PCI

The PCC range for clinical chemistry parameters included albumin, low: 0.86, millimole per liter (mmol)/L, calcium, low: 0.91, high: 1.06, glucose. Low: 0.71, high: 1.41, Potassium, low: 0.86, high: 1.10, Sodium, low: 0.96, high: 1.03, Total CO2, Low: 0.86, high: 1.14, Creatinine, in male, Low: \<75 micromole per liter (μmol/L), high: \>110 μmol/L, female, Low: \<65 μmol/L, high: \>95, Blood Urea Nitrogen (BUN), high: \>1.5xULN mmol/L, Uric Acid, in male, Low: \< 180 μmol/L, high: \> 480 μmol/L, female, Low: \< 120 μmol/L, high: \> 420. Only parameters with PCI values are reported.

Time frame:
Up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinical Biochemistry Parameters of PCI
ParticipantsPlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
Creatinine,Low1925614
Creatinine,High2212
Aspartate Amino Transferase,High1110
Potassium,High2425
Uric acid,High1011
Gamma Glutamyl Transferase,High1121
Total Bilirubin,High1111
Alanine Amino Transferase,High0200

Adverse events

Collected over Non-SAEs and SAEs were collected from start of the treatment up to Week 16.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/68 (0%)0/68 (0%)24/68 (35.3%)
FP 200 μg0/69 (0%)0/69 (0%)28/69 (40.6%)
SB-705498 12 mg0/23 (0%)0/23 (0%)13/23 (56.5%)
SB-705498 + FP 12 mg0/47 (0%)0/47 (0%)19/47 (40.4%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventPlaceboFP 200 μgSB-705498 12 mgSB-705498 + FP 12 mg
HypersensitivityImmune system disorders12/6811/697/2310/47
HeadacheNervous system disorders9/6811/695/235/47
Nasal discomfortRespiratory, thoracic and mediastinal disorders3/682/690/230/47
NasopharyngitisInfections and infestations1/681/691/231/47
DiarrhoeaGastrointestinal disorders0/680/691/230/47
VomitingGastrointestinal disorders0/680/691/230/47
PyrexiaGeneral disorders0/681/691/230/47
InfluenzaInfections and infestations0/682/690/231/47
CoughRespiratory, thoracic and mediastinal disorders1/680/690/231/47
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/680/690/231/47

Baseline characteristics

All subjects population comprised of all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Treatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then ATotal
Mean29.6 ± 5.6529.6 ± 9.2428.0 ± 5.0728.5 ± 9.2028.5 ± 6.4627.8 ± 6.3424.5 ± 3.1132.5 ± 10.5425.3 ± 1.5024.0 ± 1.0028.3 ± 6.2926.8 ± 11.0328.1 ± 6.86
Sex: Female, Male
Sex: Female, Male(Participants)Treatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then ATotal
Female42634420421133
Male36254424013337
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Treatment A First, Then B, Then DTreatment B First, Then A, Then DTreatment B, Then D, Then ATreatment A, Then D, Then BTreatment D, Then A, Then BTreatment D, Then B, Then ATreatment A, Then B, Then CTreatment B, Then A, Then CTreatment B, Then C, Then ATreatment A, Then C, Then BTreatment C, Then A, Then BTreatment C, Then B, Then ATotal
White(Wh)-Wh/Caucasian(Ca)/European(Eu)Heritage(H)78877744434467
American Indian or Alaskan Native Wh-Wh/Ca/Eu H0000100000001
Wh - Arabic/North African H0001000000001
Asian - South East Asian H0000010000001
08

Study locations

1 site
  • GSK Investigational Site
    Vienna, A-1150, Austria
09

References and documents

Publications

  • Bareille P, Murdoch RD, Denyer J, Bentley J, Smart K, Yarnall K, Zieglmayer P, Zieglmayer R, Lemell P, Horak F. The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis. Int J Clin Pharmacol Ther. 2013 Jul;51(7):576-84. doi: 10.5414/CP201890. PubMed 23735181 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2011 to primary completion in Jul 2011, 2 months.

Results were first posted in Sep 2019, 8 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2011
First posted
Aug 29, 2011
StartActual
Apr 14, 2011
Primary completionActual
Jul 7, 2011
CompletionActual
Jul 7, 2011
Results first posted
Sep 13, 2019
Last update
Sep 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01424397
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 29, 2011
Start date
Apr 14, 2011
Primary completion
Jul 7, 2011
Completion
Jul 7, 2011
Results posted
Sep 13, 2019
Last update
Sep 13, 2019

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: SB 705498 · Fluticasone

Start the discussion